Physician profile
Michael J Boyd
NPI 1891924999
$6,083.07
in general payments reported to CMS, 2019-2025
36 companies · $873 in 2025
The $873 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $433 · 2020: $138 · 2021: $802 · 2022: $1,901 · 2023: $1,134 · 2024: $803 · 2025: $873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,765 · Education: $45.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,765.03 |
| Education | $45.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $1,869.97 | 2019-2025 | Vumerity, Tysabri |
| Abbvie INC. | $1,262.36 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Teva Pharmaceuticals USA, INC. | $874.58 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Genzyme Corporation | $204.61 | 2022-2025 | |
| Sk Life Science, INC. | $180.68 | 2021-2025 | |
| Ucb, INC. | $158.92 | 2021-2025 | Nayzilam, Zilbrysq |
| Novartis Pharmaceuticals Corporation | $146.96 | 2021-2025 | |
| Genentech USA, INC. | $118.98 | 2025 | Ocrevus Zunovo |
| Lundbeck LLC | $109.18 | 2023-2025 | Vyepti, Rexulti |
| Banner Life Sciences, LLC | $102.48 | 2022-2024 | |
| Tg Therapeutics, INC. | $102.36 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $96.82 | 2020-2021 | |
| Livanova USA, INC. | $92.63 | 2021-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Lilly USA, LLC | $78.56 | 2019-2023 | Amyvid |
| Argenx US, INC. | $77.40 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $52.04 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $49.75 | 2019-2025 | Ultomiris |
| Pfizer INC. | $47.39 | 2025 | |
| Acorda Therapeutics, INC | $47.31 | 2023 | Ampyra, Inbrija |
| Kyowa Kirin, INC. | $46.72 | 2021 | |
| Emd Serono, INC. | $43.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $35.80 | 2025 | |
| Amgen INC. | $31.19 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $29.61 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $27.12 | 2022 | |
| Alnylam Pharmaceuticals INC. | $24.91 | 2021 | |
| Janssen Biotech, INC. | $24.83 | 2025 | |
| Allergan, INC. | $18.76 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $18.70 | 2025 | Rexulti |
| Impel Pharmaceuticals INC. | $18.25 | 2023 | Trudhesa |
| Acadia Pharmaceuticals INC | $17.45 | 2022 | |
| Neurelis, INC. | $16.64 | 2023 | Valtoco |
| Abbott Laboratories | $14.93 | 2024 | Infinity |
| Upsher-Smith Laboratories LLC | $14.72 | 2019 | |
| Cycle Pharmaceuticals INC | $14.33 | 2025 | Bafiertam |
| Avanir Pharmaceuticals, INC. | $13.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.